深度学习利用影像文本报告估算PD-1阻断治疗NSCLC患者的RECIST结局
本研究基于接受PD-1阻断治疗的非小细胞肺癌患者的影像学文本报告,在训练队列和两个测试队列中开发深度学习模型,用于估算金标准RECIST定义的结局。模型可准确估算最佳总体缓解和無进展生存期,有望在大规模真实世界肿瘤数据库中确定客观结局指标。
要点
- 深度学习模型可基于影像文本报告估算RECIST最佳总体缓解与无进展生存期。
- 模型在训练队列和两个测试队列中完成开发与验证。
- 该工具或可支持大规模真实世界肿瘤数据集的分析。
核心结论
- 深度学习模型可基于影像学文本报告准确估算RECIST定义的最佳总体缓解和无进展生存期。
- 该模型有望成为大规模判定结局的工具,支持大型临床数据库分析。
研究设计与样本
- 利用接受PD-1阻断治疗的非小细胞肺癌患者的影像学文本报告,在一个训练队列和两个测试队列中开发并验证深度学习模型。
主要发现
- 模型可准确估算最佳总体缓解。
- 模型可准确估算无进展生存期。
临床怎么用
- 可将模型用于大规模真实世界肿瘤数据集的客观结局判定与分析。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Real-world evidence (RWE), conclusions derived from analysis of patients not treated in clinical trials, is increasingly recognized as an opportunity for discovery, to reduce disparities, and to contribute to regulatory approval. Maximal value of RWE may be facilitated through machine-learning techniques to integrate and interrogate large and otherwise underutilized datasets. In cancer research, an ongoing challenge for RWE is the lack of reliable, reproducible, scalable assessment of treatment-specific outcomes. We hypothesized a deep-learning model could be trained to use radiology text reports to estimate gold-standard RECIST-defined outcomes. Using text reports from patients with non-small cell lung cancer treated with PD-1 blockade in a training cohort and two test cohorts, we developed a deep-learning model to accurately estimate best overall response and progression-free survival. Our model may be a tool to determine outcomes at scale, enabling analyses of large clinical databases. SIGNIFICANCE: We developed and validated a deep-learning model trained on radiology text reports to estimate gold-standard objective response categories used in clinical trial assessments. This tool may facilitate analysis of large real-world oncology datasets using objective outcome metrics determined more reliably and at greater scale than currently possible.This article is highlighted in the In This Issue feature, p. 1.
引用
- Arbour KC, Luu AT, Luo J, et al. Deep Learning to Estimate RECIST in Patients with NSCLC Treated with PD-1 Blockade. Cancer Discov. 2020. PMID: 32958579. doi:10.1158/2159-8290.CD-20-0419
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。